Dextrothyroxine

In this article, we will explore the topic of Dextrothyroxine in depth, analyzing its relevance in today's society and its impact on different aspects of our lives. From its origin and evolution to its influence on popular culture, through its involvement in the way we relate to the world around us. We will also examine expert opinions and the various perspectives that exist around Dextrothyroxine, with the aim of providing a global and complete vision of this broad and complex topic. Along these lines, we will delve into a deep reflection that will help us better understand the importance of Dextrothyroxine in the current context.
Dextrothyroxine
Clinical data
Trade namesCholoxin
Other namesD-3,5,3',5'-tetraiodothyronine
AHFS/Drugs.comMultum Consumer Information
ATC code
Legal status
Legal status
  • Discontinued
Identifiers
  • (2R)-2-amino-3-propanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.094 Edit this at Wikidata
Chemical and physical data
FormulaC15H11I4NO4
Molar mass776.874 g·mol−1
3D model (JSmol)
  • O=C(O)(N)Cc2cc(I)c(Oc1cc(I)c(O)c(I)c1)c(I)c2
  • InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m1/s1
  • Key:XUIIKFGFIJCVMT-GFCCVEGCSA-N

Dextrothyroxine (trade name Choloxin) is a dextrorotary isomer of thyroxine. It saw research as a cholesterol-lowering drug but was pulled due to cardiac side-effects. It increases hepatic lipase which in turn improves utilization of triglycerides and decreases levels of lipoprotein(a) in blood serum.

See also

References

  1. ^ "Dextrothyroxine (Code C61719)". NCI Thesaurus. National Cancer Institute. 2011-11-14. Retrieved 2020-01-28.
  2. ^ Bantle JP, Hunninghake DB, Frantz ID, Kuba K, Mariash CN, Oppenheimer JH (September 1984). "Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia". The American Journal of Medicine. 77 (3): 475–81. doi:10.1016/0002-9343(84)90107-4. PMID 6475988.
  3. ^ Bommer C, Werle E, Walter-Sack I, Keller C, Gehlen F, Wanner C, et al. (January 1998). "D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients". Journal of the American Society of Nephrology. 9 (1): 90–6. doi:10.1681/ASN.V9190. PMID 9440092.